BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of calendar year with topline data in second half of calendar year 2026IMVT-1402 development is rapidly progressing with si ...

I’m a stock analyst with an MBA and a background in healthcare, bringing years of experience as a Registered Nurse dedicated to patient care. I've had the privilege of sharing my insights on Seeking Alpha since 2017. I am most interested in identifying underlying assumptions in stock valuations by emphasizing financial modeling techniques like DCF analysis. I then provide scenario-based forecasts to help readers gauge reasonable outcomes. I am influenced by books like Superforecasting and Antifragile. As su ...

Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologicsNEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zest Health, the first value-based virtual care company focused on treating patients with inflammatory skin diseases, today announced $13 million in seed funding. Zest Health’s platform provides personalized dermatology care that minimizes unnecessary pharmaceutical utilization while producing sustainable clinical outc ...

BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 10, 2025, to report its financial results for the third quarter ended December 31, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in ...

Group 1 - Roivant Sciences Ltd. (NASDAQ: ROIV) is executing its "Vant" biotech business model, which allows for the rapid development and monetization of drug candidates through specialized subsidiaries [1] - The company's trials have shown promising progress since the last report, indicating potential advancements in their drug development pipeline [1]

Financial Data and Key Metrics Changes - The company reported a loss for continuing operations of $237 million, with an adjusted loss of $219 million [57] - Research and development expenses were $143 million, with adjusted R&D non-GAAP at $132 million [57] - The company ended the quarter with a strong cash position of $5.4 billion, having repurchased $754 million worth of stock as of September 30 [9][58] Business Line Data and Key Metrics Changes - The company is focused on clinical trial execution, with ongoing trials expected to generate significant data in the near future [7] - The NIU Phase 2 study for brepocitinib showed sustained improvement in key metrics at 52 weeks, with only one additional treatment failure in each dose arm [14][25] - The company has initiated a Phase 2 study of mosli in pulmonary hypertension associated with interstitial lung disease [8] Market Data and Key Metrics Changes - The JAK inhibitors market has doubled since 2020 in terms of treated patients and revenue, indicating a growing acceptance among physicians and patients [16] - The prevalence of non-infectious uveitis (NIU) is estimated at 70,000 to 100,000 patients, with high morbidity and limited treatment options available [19] Company Strategy and Development Direction - The company aims to leverage its late-stage pipeline, including IMVT-1402 and batoclimab, to achieve a peak sales portfolio exceeding $10 billion across multiple therapeutic areas [12] - The company is actively pursuing business development opportunities, with multiple negotiations for potential in-licensing of new programs [10] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the upcoming data readouts and the potential for significant value creation in the next 18 months [55] - The company is optimistic about the business development environment and is preparing for future announcements regarding new programs [56] Other Important Information - The company has made progress in its LNP litigation, with a Markman hearing scheduled for December [9] - The company is committed to returning capital to shareholders while being prudent in capital deployment [9] Q&A Session Summary Question: What efficacy is expected in the Phase 3 NIU trial? - Management hopes to see efficacy similar to that observed in Phase 2, with a wide margin relative to competitors like Humira [61][62] Question: What is the latest update on HS? - Management is pleased with the work done on indication expansion for brepocitinib, and HS remains on the radar for potential development [63] Question: Are there specific steroid dose requirements for the CLARITY trial? - There is no specific requirement for steroid doses; patients can be on any background steroid dose up to 40 mg per day [68] Question: What are the thoughts on pricing for brepocitinib? - Pricing is still premature to determine, but management considers a wide range of prices supportable, with benchmarks around $100,000 for similar orphan drugs [72][73] Question: What placebo response is assumed for the uveitis Phase 3 trial? - The base case assumption is a placebo rate similar to that seen in the VISUAL I study, with the study designed to be overpowered to detect differences [75][76] Question: How will brepocitinib be positioned against Humira biosimilars? - The expectation is for brepocitinib to be predominantly used in the TNF refractory population, with a significant unmet need in NIU [91][93]

Financial Results and Business Update for the Quarter Ended September 30, 2024 roivant November 12, 2024 Forward-Looking Statements This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financia ...

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -38.10%. A quarter ago, it was expected that this company would post a loss of $0.21 per share when it actually produced a loss of $0.18, delivering a surprise of 14.29%.Over the last four quarters, the company has s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40782 ROIVANT SCIENCES LTD. (Exact name of Registrant as specified in its Charter) Bermuda 98-1173944 (State or other jurisdiction of incorporation or organi ...

BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" ...